NDAINTRA-ARTERIALSOLUTION
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
18/100
Data completeness
3/8 — Basic
IOMERVU (iomeprol injection) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2024.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOMERVU (iomeprol injection) is a non-ionic, low-osmolality radiographic contrast agent administered intra-arterially to enhance X-ray imaging during diagnostic procedures. It works through X-ray contrast activity to improve visualization of blood vessels and tissue structures during angiographic examinations. The product targets patients undergoing coronary, cerebral, or peripheral angiography who require enhanced radiographic imaging.
Growth3.1 years to LOE
Early-stage launch positions IOMERVU for growth in the contrast agent market; commercial teams will focus on hospital and imaging center adoption strategies.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Why This Matters for Your Career
Worked on IOMERVU at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.